DVAXW实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary ():

Stats
今日成交量	0
平均成交量	0
市值	0
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Dynavax Technologies 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Dynavax Technologies 财务报表

Annual	2020
营收:	$46.55M
毛利润:	$32.64M (70.12 %)
EPS:	$-0.750

FY	2020
营收:	$46.55M
毛利润:	$32.64M (70.12 %)
EPS:	$-0.750

FY	2019
营收:	$35.22M
毛利润:	$15.83M (44.95 %)
EPS:	$0

FY	2018
营收:	$8.20M
毛利润:	$-13.60M (-165.87 %)
EPS:	$0

Financial Reports:

No articles found.

Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.